Gravity Pharma terminates $2.9M brand license agreement ab initio for Synergy CHC

Synergy CHC Corp.

Gravity Pharma terminated Brand License Agreement ab initio for FOCUSfactor and Flat Tummy Co. products in UAE & Turkey.
Agreement provided exclusive license for $2.9M aggregate fee previously recognized as revenue by Synergy CHC.
Company continues pursuing registration and marketing of licensed IP in the Territory.

This headline and bullets were generated automatically by deepseek-v4-flash:cloud@v2 from the public filing. Read the source on SEC.gov before relying on any specific claim. Not investment advice. See methodology for how this pipeline works.